1. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.
- Author
-
Abboud, Hesham, Probasco, John C, Irani, Sarosh, Ances, Beau, Benavides, David R, Bradshaw, Michael, Christo, Paulo Pereira, Dale, Russell C, Fernandez-Fournier, Mireya, Flanagan, Eoin P, Gadoth, Avi, George, Pravin, Grebenciucova, Elena, Jammoul, Adham, Lee, Soon-Tae, Li, Yuebing, Matiello, Marcelo, Morse, Anne Marie, Rae-Grant, Alexander, Rojas, Galeno, Rossman, Ian, Schmitt, Sarah, Venkatesan, Arun, Vernino, Steven, Pittock, Sean J, Titulaer, Maarten J, and Autoimmune Encephalitis Alliance Clinicians Network
- Subjects
Autoimmune Encephalitis Alliance Clinicians Network ,Humans ,Encephalitis ,Autoimmune Diseases ,Adrenal Cortex Hormones ,Immunoglobulins ,Intravenous ,Treatment Outcome ,Plasmapheresis ,autoimmune encephalitis ,neuroimmunology ,paraneoplastic syndrome ,Clinical Research ,Autoimmune Disease ,Brain Disorders ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery - Abstract
The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune encephalitis as a broad category rather than focusing on individual antibody syndromes. Core authors from the Autoimmune Encephalitis Alliance Clinicians Network reviewed literature and developed the first draft. Where evidence was lacking or controversial, an electronic survey was distributed to all members to solicit individual responses. Sixty-eight members from 17 countries answered the survey. Corticosteroids alone or combined with other agents (intravenous IG or plasmapheresis) were selected as a first-line therapy by 84% of responders for patients with a general presentation, 74% for patients presenting with faciobrachial dystonic seizures, 63% for NMDAR-IgG encephalitis and 48.5% for classical paraneoplastic encephalitis. Half the responders indicated they would add a second-line agent only if there was no response to more than one first-line agent, 32% indicated adding a second-line agent if there was no response to one first-line agent, while only 15% indicated using a second-line agent in all patients. As for the preferred second-line agent, 80% of responders chose rituximab while only 10% chose cyclophosphamide in a clinical scenario with unknown antibodies. Detailed survey results are presented in the manuscript and a summary of the diagnostic and therapeutic recommendations is presented at the conclusion.
- Published
- 2021